
Mengchang Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2284469/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget, 2016, 7, 27753-27763.	1.8	19
2	Norepinephrineâ€CREB1â€miRâ€373 axis promotes progression of colon cancer. Molecular Oncology, 2020, 14, 1059-1073.	4.6	16
3	Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old. Oncology Letters, 2016, 12, 5205-5210.	1.8	7
4	Gene expression profile of multiple myeloma cell line treated by arsenic trioxide. Journal of Huazhong University of Science and Technology [Medical Sciences], 2007, 27, 646-649.	1.0	6
5	As ₄ S ₄ Exhibits Good Killing Effect on Multiple Myeloma Cells Via Repressing SOCS1 Methylation-Mediated JAK2/STAT3 Signaling Pathway. Technology in Cancer Research and Treatment, 2019, 18, 153303381989680.	1.9	4
6	Silence of MCL-1 upstream signaling by shRNA abrogates multiple myeloma growth. Experimental Hematology and Oncology, 2014, 3, 27.	5.0	3
7	Arsenic Trioxide Combined with VCMP or VAD Chemotherapy in Patients with Refractory or Relapsed Multiple Myeloma in a Single Institution of China. Indian Journal of Hematology and Blood Transfusion, 2014, 30, 259-264.	0.6	1
8	Small Molecule Bda-366 As a Bcl2-BH4 Antagonist for Multiple Myeloma Therapy. Blood, 2015, 126, 2049-2049.	1.4	0